Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 3, Issue 21
November 12 2019
Issue Cover

Table of Contents

POINT-COUNTERPOINT

Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?
Felicitas Thol,Uwe Platzbecker
View Articletitled, Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?
Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?
Guillermo F. Sanz,Mariam Ibañez,Esperanza Such
View Articletitled, Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?

EXCEPTIONAL CASE REPORTS

Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia
Clinical Trials & Observations
Fares Alsawah,Lydia Benitez,Sarah Choi,Bernard Marini,Anthony Perissinotti,Amy Skyles,Patrick Burke,Kristen Pettit,Ashley Crouch,Heather Fox,Dale Bixby
View Articletitled, Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia
Thrombotic thrombocytopenic purpura and defective apoptosis due to CASP8/10 mutations: the role of mycophenolate mofetil
Clinical Trials & Observations
F. Fioredda,E. Cappelli,A. Mariani,A. Beccaria,E. Palmisani,A. Grossi,I. Ceccherini,R. Venè,C. Micalizzi,M. Calvillo,F. Pierri,I. Mancini,F. Peyvandi,F. Corsolini,C. Dufour,M. Miano
View Articletitled, Thrombotic thrombocytopenic purpura and defective apoptosis due to CASP8/10 mutations: the role of mycophenolate mofetil

STIMULUS REPORTS

Patent ductus arteriosus generates neonatal hemolytic jaundice with thrombocytopenia in Upshaw-Schulman syndrome
Yoshihiro Fujimura,Bernhard Lämmle,Saori Tanabe,Kazuya Sakai,Toshiyuki Kimura,Koichi Kokame,Toshiyuki Miyata,Yukihiro Takahashi,Shigeki Taniguchi,Masanori Matsumoto
View Articletitled, Patent ductus arteriosus generates neonatal hemolytic jaundice with thrombocytopenia in Upshaw-Schulman syndrome
Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients
Clinical Trials & Observations
Margherita Maffioli,Toni Giorgino,Barbara Mora,Alessandra Iurlo,Elena Elli,Maria Chiara Finazzi,Marianna Caramella,Elisa Rumi,Maria Cristina Carraro,Nicola Polverelli,Mariella D’Adda,Simona Malato,Marianna Rossi,Alfredo Molteni,Alessandro Vismara,Cinzia Sissa,Francesco Spina,Michela Anghilieri,Daniele Cattaneo,Rossella Renso,Marta Bellini,Maria Luisa Pioltelli,Chiara Cavalloni,Daniela Barraco,Raffaella Accetta,Lorenza Bertù,Matteo Giovanni Della Porta,Francesco Passamonti
View Articletitled, Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients
Supplemental data
Cranberry A-type proanthocyanidins selectively target acute myeloid leukemia cells
Laura M. Bystrom,Daniel P. Bezerra,Hsiao-Ting Hsu,Hongliang Zong,Luis A. Lara-Martínez,Jeanne P. De Leon,Megan Emmanuel,David Méry,Sara Gardenghi,Duane Hassane,Catherine C. Neto,Susanna Cunningham-Rundles,Michael W. Becker,Stefano Rivella,Monica L. Guzman
View Articletitled, Cranberry A-type proanthocyanidins selectively target acute myeloid leukemia cells
Supplemental data

REVIEW ARTICLES

Microbiota modification in hematology: still at the bench or ready for the bedside?
Clinical Trials & Observations
Christopher J. Severyn,Ryan Brewster,Tessa M. Andermann
View Articletitled, Microbiota modification in hematology: still at the bench or ready for the bedside?
CAR T-cell therapy: is it prime time in myeloma?
Surbhi Sidana,Nina Shah
View Articletitled, CAR T-cell therapy: is it prime time in myeloma?
New therapies for von Willebrand disease
Pier Mannuccio Mannucci
View Articletitled, New therapies for von Willebrand disease

SYSTEMATIC REVIEW

Impact of γδ T cells on clinical outcome of hematopoietic stem cell transplantation: systematic review and meta-analysis
Lucas C. M. Arruda,Ahmed Gaballa,Michael Uhlin
View Articletitled, Impact of γδ T cells on clinical outcome of hematopoietic stem cell transplantation: systematic review and meta-analysis
Supplemental data

CLINICAL TRIALS AND OBSERVATIONS

Association between clinical outcomes and metformin use in adults with sickle cell disease and diabetes mellitus
Clinical Trials & Observations
Sherif M. Badawy,Amanda B. Payne
View Articletitled, Association between clinical outcomes and metformin use in adults with sickle cell disease and diabetes mellitus
Supplemental data
Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation
Clinical Trials & Observations
Mi Kwon,Rebeca Bailén,María Jesús Pascual-Cascón,Ana Isabel Gallardo-Morillo,Abel García Sola,Pascual Balsalobre,Laura Solán,Nieves Dorado,Cristina Muñoz,David Serrano,Carolina Martínez-Laperche,Ismael Buño,Javier Anguita,José Luis Díez-Martin,on behalf of Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH),on behalf of Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH),on behalf of Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH),on behalf of Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH),on behalf of Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH),on behalf of Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH),on behalf of Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH),on behalf of Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH),on behalf of Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH),on behalf of Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH),on behalf of Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH),on behalf of Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH),on behalf of Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH),on behalf of Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH)
View Articletitled, Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation

GENE THERAPY

Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B
Annette Von Drygalski,Adam Giermasz,Giancarlo Castaman,Nigel S. Key,Susan Lattimore,Frank W. G. Leebeek,Wolfgang Miesbach,Michael Recht,Alison Long,Robert Gut,Eileen K. Sawyer,Steven W. Pipe
View Articletitled, Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B
Supplemental data
Genome editing of HBG1 and HBG2 to induce fetal hemoglobin
Jean-Yves Métais,Phillip A. Doerfler,Thiyagaraj Mayuranathan,Daniel E. Bauer,Stephanie C. Fowler,Matthew M. Hsieh,Varun Katta,Sagar Keriwala,Cicera R. Lazzarotto,Kevin Luk,Michael D. Neel,S. Scott Perry,Samuel T. Peters,Shaina N. Porter,Byoung Y. Ryu,Akshay Sharma,Devlin Shea,John F. Tisdale,Naoya Uchida,Scot A. Wolfe,Kaitly J. Woodard,Yuxuan Wu,Yu Yao,Jing Zeng,Shondra Pruett-Miller,Shengdar Q. Tsai,Mitchell J. Weiss
View Articletitled, Genome editing of <em>HBG1</em> and <em>HBG2</em> to induce fetal hemoglobin
Supplemental data

HEALTH SERVICES AND OUTCOMES

Associations between hematology/oncology fellows’ training and mentorship experiences and hematology-only career plans
Leah E. Masselink,Clese E. Erikson,Nathan T. Connell,Laura M. De Castro,Georgette A. Dent,Ariela L. Marshall,Rakhi P. Naik,Marquita Nelson,Casey L. O’Connell,Anita Rajasekhar,Deva Sharma,Melody Smith,Alfred Ian Lee
View Articletitled, Associations between hematology/oncology fellows’ training and mentorship experiences and hematology-only career plans
Supplemental data

HEMATOPOIESIS AND STEM CELLS

Replication timing alterations in leukemia affect clinically relevant chromosome domains
Juan Carlos Rivera-Mulia,Takayo Sasaki,Claudia Trevilla-Garcia,Naoto Nakamichi,David J. H. F. Knapp,Colin A. Hammond,Bill H. Chang,Jeffrey W. Tyner,Meenakshi Devidas,Jared Zimmerman,Kyle N. Klein,Vivek Somasundaram,Brian J. Druker,Tanja A. Gruber,Amnon Koren,Connie J. Eaves,David M. Gilbert
View Articletitled, Replication timing alterations in leukemia affect clinically relevant chromosome domains
Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma
Andrea Schmidts,Maria Ormhøj,Bryan D. Choi,Allison O. Taylor,Amanda A. Bouffard,Irene Scarfò,Rebecca C. Larson,Matthew J. Frigault,Kathleen Gallagher,Ana P. Castano,Lauren S. Riley,Maria L. Cabral,Angela C. Boroughs,Rubí M.-H. Velasco Cárdenas,Wolfgang Schamel,Jing Zhou,Sean Mackay,Yu-Tzu Tai,Kenneth C. Anderson,Marcela V. Maus
View Articletitled, Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma
Supplemental data

LYMPHOID NEOPLASIA

Targeting cyclooxygenase by indomethacin decelerates progression of acute lymphoblastic leukemia in a xenograft model
Nina Richartz,Eva Duthil,Anthony Ford,Elin Hallan Naderi,Sampada Bhagwat,Karin M. Gilljam,Marta Maria Burman,Ellen Ruud,Heidi Kiil Blomhoff,Seham Skah
View Articletitled, Targeting cyclooxygenase by indomethacin decelerates progression of acute lymphoblastic leukemia in a xenograft model
Supplemental data
Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma
Yu-Hsiu T. Lin,Gregory P. Way,Benjamin G. Barwick,Margarette C. Mariano,Makeba Marcoulis,Ian D. Ferguson,Christoph Driessen,Lawrence H. Boise,Casey S. Greene,Arun P. Wiita
View Articletitled, Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma
Supplemental data
Induction of multiple myeloma bone marrow stromal cell apoptosis by inhibiting extracellular vesicle miR-10a secretion
Tomohiro Umezu,Satoshi Imanishi,Seiichiro Yoshizawa,Chiaki Kawana,Junko H. Ohyashiki,Kazuma Ohyashiki
View Articletitled, Induction of multiple myeloma bone marrow stromal cell apoptosis by inhibiting extracellular vesicle <em>miR-10a</em> secretion
Supplemental data
Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells
Tomasz Sewastianik,Maria Luisa Guerrera,Keith Adler,Peter S. Dennis,Kyle Wright,Vignesh Shanmugam,Ying Huang,Helen Tanton,Meng Jiang,Amanda Kofides,Maria G. Demos,Audrey Dalgarno,Neil A. Patel,Anwesha Nag,Geraldine S. Pinkus,Guang Yang,Zachary R. Hunter,Petr Jarolim,Nikhil C. Munshi,Steven P. Treon,Ruben D. Carrasco
View Articletitled, Human <em>MYD88</em><sup>L265P</sup> is insufficient by itself to drive neoplastic transformation in mature mouse B cells
Supplemental data
More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling
Peter Bader,Emilia Salzmann-Manrique,Adriana Balduzzi,Jean-Hugues Dalle,Ann E. Woolfrey,Merav Bar,Michael R. Verneris,Michael J. Borowitz,Nirali N. Shah,Nathan Gossai,Peter J. Shaw,Allen R. Chen,Kirk R. Schultz,Hermann Kreyenberg,Lucia Di Maio,Gianni Cazzaniga,Cornelia Eckert,Vincent H. J. van der Velden,Rosemary Sutton,Arjan Lankester,Christina Peters,Thomas E. Klingebiel,Andre M. Willasch,Stephan A. Grupp,Michael A. Pulsipher,on behalf of the Children’s Oncology Group, the Pediatric Blood & Marrow Transplant Consortium, the Australian Transplantation Group, the International Berlin-Frankfurt-Münster Study Group, the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation, and the Westhafen Intercontinental Group,on behalf of the Children’s Oncology Group, the Pediatric Blood & Marrow Transplant Consortium, the Australian Transplantation Group, the International Berlin-Frankfurt-Münster Study Group, the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation, and the Westhafen Intercontinental Group,on behalf of the Children’s Oncology Group, the Pediatric Blood & Marrow Transplant Consortium, the Australian Transplantation Group, the International Berlin-Frankfurt-Münster Study Group, the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation, and the Westhafen Intercontinental Group,on behalf of the Children’s Oncology Group, the Pediatric Blood & Marrow Transplant Consortium, the Australian Transplantation Group, the International Berlin-Frankfurt-Münster Study Group, the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation, and the Westhafen Intercontinental Group,on behalf of the Children’s Oncology Group, the Pediatric Blood & Marrow Transplant Consortium, the Australian Transplantation Group, the International Berlin-Frankfurt-Münster Study Group, the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation, and the Westhafen Intercontinental Group,on behalf of the Children’s Oncology Group, the Pediatric Blood & Marrow Transplant Consortium, the Australian Transplantation Group, the International Berlin-Frankfurt-Münster Study Group, the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation, and the Westhafen Intercontinental Group,on behalf of the Children’s Oncology Group, the Pediatric Blood & Marrow Transplant Consortium, the Australian Transplantation Group, the International Berlin-Frankfurt-Münster Study Group, the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation, and the Westhafen Intercontinental Group,on behalf of the Children’s Oncology Group, the Pediatric Blood & Marrow Transplant Consortium, the Australian Transplantation Group, the International Berlin-Frankfurt-Münster Study Group, the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation, and the Westhafen Intercontinental Group,on behalf of the Children’s Oncology Group, the Pediatric Blood & Marrow Transplant Consortium, the Australian Transplantation Group, the International Berlin-Frankfurt-Münster Study Group, the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation, and the Westhafen Intercontinental Group,on behalf of the Children’s Oncology Group, the Pediatric Blood & Marrow Transplant Consortium, the Australian Transplantation Group, the International Berlin-Frankfurt-Münster Study Group, the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation, and the Westhafen Intercontinental Group,on behalf of the Children’s Oncology Group, the Pediatric Blood & Marrow Transplant Consortium, the Australian Transplantation Group, the International Berlin-Frankfurt-Münster Study Group, the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation, and the Westhafen Intercontinental Group,on behalf of the Children’s Oncology Group, the Pediatric Blood & Marrow Transplant Consortium, the Australian Transplantation Group, the International Berlin-Frankfurt-Münster Study Group, the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation, and the Westhafen Intercontinental Group,on behalf of the Children’s Oncology Group, the Pediatric Blood & Marrow Transplant Consortium, the Australian Transplantation Group, the International Berlin-Frankfurt-Münster Study Group, the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation, and the Westhafen Intercontinental Group,on behalf of the Children’s Oncology Group, the Pediatric Blood & Marrow Transplant Consortium, the Australian Transplantation Group, the International Berlin-Frankfurt-Münster Study Group, the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation, and the Westhafen Intercontinental Group,on behalf of the Children’s Oncology Group, the Pediatric Blood & Marrow Transplant Consortium, the Australian Transplantation Group, the International Berlin-Frankfurt-Münster Study Group, the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation, and the Westhafen Intercontinental Group,on behalf of the Children’s Oncology Group, the Pediatric Blood & Marrow Transplant Consortium, the Australian Transplantation Group, the International Berlin-Frankfurt-Münster Study Group, the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation, and the Westhafen Intercontinental Group,on behalf of the Children’s Oncology Group, the Pediatric Blood & Marrow Transplant Consortium, the Australian Transplantation Group, the International Berlin-Frankfurt-Münster Study Group, the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation, and the Westhafen Intercontinental Group,on behalf of the Children’s Oncology Group, the Pediatric Blood & Marrow Transplant Consortium, the Australian Transplantation Group, the International Berlin-Frankfurt-Münster Study Group, the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation, and the Westhafen Intercontinental Group,on behalf of the Children’s Oncology Group, the Pediatric Blood & Marrow Transplant Consortium, the Australian Transplantation Group, the International Berlin-Frankfurt-Münster Study Group, the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation, and the Westhafen Intercontinental Group,on behalf of the Children’s Oncology Group, the Pediatric Blood & Marrow Transplant Consortium, the Australian Transplantation Group, the International Berlin-Frankfurt-Münster Study Group, the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation, and the Westhafen Intercontinental Group,on behalf of the Children’s Oncology Group, the Pediatric Blood & Marrow Transplant Consortium, the Australian Transplantation Group, the International Berlin-Frankfurt-Münster Study Group, the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation, and the Westhafen Intercontinental Group,on behalf of the Children’s Oncology Group, the Pediatric Blood & Marrow Transplant Consortium, the Australian Transplantation Group, the International Berlin-Frankfurt-Münster Study Group, the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation, and the Westhafen Intercontinental Group,on behalf of the Children’s Oncology Group, the Pediatric Blood & Marrow Transplant Consortium, the Australian Transplantation Group, the International Berlin-Frankfurt-Münster Study Group, the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation, and the Westhafen Intercontinental Group,on behalf of the Children’s Oncology Group, the Pediatric Blood & Marrow Transplant Consortium, the Australian Transplantation Group, the International Berlin-Frankfurt-Münster Study Group, the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation, and the Westhafen Intercontinental Group,on behalf of the Children’s Oncology Group, the Pediatric Blood & Marrow Transplant Consortium, the Australian Transplantation Group, the International Berlin-Frankfurt-Münster Study Group, the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation, and the Westhafen Intercontinental Group
View Articletitled, More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling
Supplemental data

MYELOID NEOPLASIA

Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation
Clinical Trials & Observations
Chihiro Yamamoto,Hirotomo Nakashima,Takashi Ikeda,Shin-ichiro Kawaguchi,Yumiko Toda,Shoko Ito,Kiyomi Mashima,Takashi Nagayama,Kento Umino,Daisuke Minakata,Hirofumi Nakano,Kaoru Morita,Ryoko Yamasaki,Miyuki Sugimoto,Yuko Ishihara,Masahiro Ashizawa,Kaoru Hatano,Kazuya Sato,Iekuni Oh,Shin-ichiro Fujiwara,Masuzu Ueda,Ken Ohmine,Kazuo Muroi,Yoshinobu Kanda
View Articletitled, Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation
Supplemental data
Human models of NUP98-KDM5A megakaryocytic leukemia in mice contribute to uncovering new biomarkers and therapeutic vulnerabilities
Sophie Cardin,Mélanie Bilodeau,Mathieu Roussy,Léo Aubert,Thomas Milan,Loubna Jouan,Alexandre Rouette,Louise Laramée,Patrick Gendron,Jean Duchaine,Hélène Decaluwe,Jean-François Spinella,Stéphanie Mourad,Françoise Couture,Daniel Sinnett,Élie Haddad,Josette-Renée Landry,Jing Ma,R. Keith Humphries,Philippe P. Roux,Josée Hébert,Tanja A. Gruber,Brian T. Wilhelm,Sonia Cellot
View Articletitled, Human models of NUP98-KDM5A megakaryocytic leukemia in mice contribute to uncovering new biomarkers and therapeutic vulnerabilities
Supplemental data
Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome
Emily F. Mason,Robert P. Hasserjian,Nidhi Aggarwal,Adam C. Seegmiller,Olga Pozdnyakova
View Articletitled, Blast phenotype and comutations in acute myeloid leukemia with mutated <em>NPM1</em> influence disease biology and outcome
Supplemental data
Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia
Clinical Trials & Observations
Qiu-Sha Huang,Jing-Zhi Wang,Ya-Zhen Qin,Qiao-Zhu Zeng,Qian Jiang,Hao Jiang,Jin Lu,Hui-Xin Liu,Yi Liu,Jing-Bo Wang,Li Su,Hong-Yu Zhang,Zhen-Ling Li,Su-Jun Gao,Bo Huang,Yu-Ying Liu,Yan-Rong Liu,Lan-Ping Xu,Xiao-Jun Huang,Xiao-Hui Zhang
View Articletitled, Overexpression of <em>WT1</em> and <em>PRAME</em> predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia
Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

Large-scale in vitro production of red blood cells from human peripheral blood mononuclear cells
Steven Heshusius,Esther Heideveld,Patrick Burger,Marijke Thiel-Valkhof,Erica Sellink,Eszter Varga,Elina Ovchynnikova,Anna Visser,Joost H. A. Martens,Marieke von Lindern,Emile van den Akker
View Articletitled, Large-scale in vitro production of red blood cells from human peripheral blood mononuclear cells
Supplemental data

THROMBOSIS AND HEMOSTASIS

Thrombus stability explains the factor V Leiden paradox: a mouse model
S. A. Shaya,R. J. Westrick,P. L. Gross
View Articletitled, Thrombus stability explains the factor V Leiden paradox: a mouse model

TRANSPLANTATION

Increased Mac-2 binding protein glycan isomer in patients at risk for late nonrelapse mortality after HSCT
Clinical Trials & Observations
Yu Akahoshi,Hideki Nakasone,Koji Kawamura,Machiko Kusuda,Shunto Kawamura,Junko Takeshita,Nozomu Yoshino,Yukiko Misaki,Kazuki Yoshimura,Ayumi Gomyo,Aki Tanihara,Masaharu Tamaki,Shun-ichi Kimura,Shinichi Kako,Yoshinobu Kanda
View Articletitled, Increased Mac-2 binding protein glycan isomer in patients at risk for late nonrelapse mortality after HSCT
Supplemental data
Blockade of TIM-1 on the donor graft ameliorates graft-versus-host disease following hematopoietic cell transplantation
Bettina P. Iliopoulou,Katie Hsu,Magdiel Pérez-Cruz,Sai-Wen Tang,Wendy W. Pang,Tom Erkers,Neeraja Kambham,Gordon J. Freeman,Rosemarie H. Dekruyff,Everett H. Meyer
View Articletitled, Blockade of TIM-1 on the donor graft ameliorates graft-versus-host disease following hematopoietic cell transplantation
Supplemental data
  • Cover Image

    Cover Image

    issue cover

    COVER FIGURE
    Giemsa-stained touch preparation from the spleen showing infiltration of NUP98-KDM5A megakaryocytic leukemia cells in a secondary human xenograft recipient mouse 33 weeks after transplantation (original magnification ×1000) See the article by Cardin et al.

  • PDF Icon PDF LinkFront Matter
  • PDF Icon PDF LinkEditorial Board
All Issues

Advertisement intended for health care professionals

Where there is smoke, there is fire: afib in SCD
Deferiprone and idiosyncrasic neutropenia: light and shadow
Nording H, Baron L, Sauter M, et al. Platelets regulate ischemia-induced revascularization and angiogenesis by secretion of growth factor–modulating factors. Blood Adv. 2023;7(21):6411-6427.
Sewastianik T, Guerrera ML, Adler K, et al. Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells. Blood Adv. 2019;3(21):3360-3374.
Medicaid Coverage Continuity is Associated with Lymphoma Stage among Children and Adolescents/Young Adults

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals